Kate Hermans and Feng Tian
August 17, 2022 07:27 AM EDT
People
R&D

Squeezed by As­traZeneca/Dai­ichi Sankyo, biotech de­vel­op­ing HER2 ADC switch­es CEO, launch­es pipeline re­view

Amber Tong

When Am­brx Bio­phar­ma went pub­lic in the sum­mer of 2021 — join­ing in on the go-go times in biotech — ex­ecs cel­e­brat­ed it as the cul­mi­na­tion of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J takes 340B fight with fed­er­al gov­ern­ment to court

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times